This special focus issue brings to the Journal of Religious Ethics fresh considerations of moral anthropology as practiced by four emergent voices within the field. Each of these essays, in varying ways, seeks not only to advance an understanding of ethics in a particular time, place, and context, but to draw our attention to shared aspects of the human condition: its discontinuities and fractures, its practices of perception and attention, its interplays of emotion, intuition, and reason, and its thoroughly intersubjective nature. To learn something of Thai Buddhist life‐worlds, contemporary Russian modes of being, or the experience of immorality in today's China, each essay argues in turn, is to gain new insight into ourselves.

No abstract

I argue that three recent studies (Imagining the Life Course, by Nancy Eberhardt; Sensory Biographies, by Robert Desjarlais; and How to Behave, by Anne Hansen) advance the field of Buddhist Ethics in the direction of the empirical study of morality. I situate their work within a larger context of moral anthropology, that is, the study of human nature in its limits and capacities for moral agency. Each of these books offers a finely grained account of particular and local Buddhist ways of interpreting human life and morality, and each explores complex conceptions of moral agency. I suggest that these three studies share similar interests in moral psychology, the human being across time, the intersubjective dimensions of moral experience, and what life within a karmic framework looks like. I propose that their contributions offer some of the most refreshing and interesting work generated in Buddhist ethics in the last decade.

Primary hypothyroidism severely impacts the quality of life of patients through a decrease in the production of the thyroid hormones T3 and T4, leading to symptoms affecting cardiovascular, neurological, cognitive, and metabolic function. The incidence rate of primary hypothyroidism is expected to increase in the near future, partially due to increasing survival of patients that have undergone radiotherapy for head and neck cancer, which induces this disease in over half of those treated. The current standard of care encompasses thyroid hormone replacement therapy, traditionally in the form of synthetic T4. However, there is mounting evidence that this is unable to restore thyroid hormone signaling in all tissues due to often persistent symptoms. Additional complications are also present in the form of dosage difficulties, extensive drug interactions and poor patience compliance. The alternative therapeutic approach employed in the past is combination therapy, which consists of administration of both T3 and T4, either synthetic or in the form of desiccated thyroid extract. Here, issues are present regarding the lack of regulation concerning formulation and lack of data regarding safety and efficacy of these treatment methods. Tissue engineering and regenerative medicine have been applied in conjunction with each other to restore function of various tissues. Recently, these techniques have been adapted for thyroid tissue, primarily through the fabrication of regenerative scaffolds. Those currently under investigation are composed of either biopolymers or native decellularized extracellular matrix (dECM) in conjunction with either primary thyrocytes or stem cells which have undergone directed thyroid differentiation. Multiple of these scaffolds have successfully restored an athyroid phenotype in vivo. However, further work is needed until clinical translation can be achieved. This is proposed in the form of exploration and combination of materials used to fabricate these scaffolds, the addition of peptides which can aid restoration of tissue homeostasis and additional in vivo experimentation providing data on safety and efficacy of these implants.